A Study of PRT1419 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia 1 (MCL1)
inhibitor, in patients with advanced solid tumors. The purpose of this study is to define the
dosing schedule, maximally tolerated dose and/or estimate the optimal biological dose to be
used in subsequent development of PRT1419.